140 related articles for article (PubMed ID: 30672056)
1. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
Robertson SJ; Ibrahim MFK; Stober C; Hilton J; Kos Z; Mazzarello S; Ramsay T; Fergusson D; Vandermeer L; Mallick R; Arnaout A; Dent SF; Segal R; Sehdev S; Gertler S; Hutton B; Clemons M
J Eval Clin Pract; 2019 Apr; 25(2):196-204. PubMed ID: 30672056
[TBL] [Abstract][Full Text] [Related]
2. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
3. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer.
de Lima MAG; Clemons M; Van Katwyk S; Stober C; Robertson SJ; Vandermeer L; Fergusson D; Thavorn K
J Eval Clin Pract; 2020 Jun; 26(3):889-892. PubMed ID: 31287198
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
Hou Y; Zynger DL; Li X; Li Z
Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
[TBL] [Abstract][Full Text] [Related]
8. Results of PONDx, a prospective multicenter study of the Oncotype DX
Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
[TBL] [Abstract][Full Text] [Related]
9. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
10. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
11. The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Bhargava R; Clark BZ; Carter GJ; Brufsky AM; Dabbs DJ
Mod Pathol; 2020 Aug; 33(8):1563-1570. PubMed ID: 32203092
[TBL] [Abstract][Full Text] [Related]
12. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
Robertson SJ; Pond GR; Hilton J; Petkiewicz SL; Ayroud Y; Kos Z; Gravel DH; Stober C; Vandermeer L; Arnaout A; Clemons M
Clin Breast Cancer; 2020 Feb; 20(1):61-67. PubMed ID: 31551182
[TBL] [Abstract][Full Text] [Related]
13. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
14. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
15. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Farrugia DJ; Landmann A; Zhu L; Diego EJ; Johnson RR; Bonaventura M; Soran A; Dabbs DJ; Clark BZ; Puhalla SL; Jankowitz RC; Brufsky AM; Lembersky BC; Ahrendt GM; McAuliffe PF; Bhargava R
Mod Pathol; 2017 Aug; 30(8):1078-1085. PubMed ID: 28548119
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
17. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
[TBL] [Abstract][Full Text] [Related]
18. Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study.
Awan AA; Saunders D; Pond G; Hamm C; Califaretti N; Mates M; Kumar V; Ibrahim MFK; Beltran-Bless AA; Vandermeer L; Hilton J; Clemons M
Curr Oncol; 2024 Feb; 31(3):1278-1290. PubMed ID: 38534929
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients.
Cheng V; Markarian A; de Lemos ML; Schaff K
J Oncol Pharm Pract; 2019 Jul; 25(5):1167-1173. PubMed ID: 30348071
[TBL] [Abstract][Full Text] [Related]
20. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
